284 results about "Non covalent" patented technology

The invention belongs to the technical field of biological medicines, and particularly discloses an epidermal growth factor-linker polypeptide-collagen, and the linker polypeptide has an amino acid sequence as shown in SEQ ID No.1. The linker polypeptide capable of connecting the EGF and the collagen is designed and synthesized, the N end of the linker polypeptide simulates an EGF receptor structure and can be combined with the EGF, and the linker polypeptide is connected with the EGF through non-covalent Van der Waals force, so that the structure of the EGF cannot be damaged; the C terminal of the linker polypeptide is rich in lysine residues, and can be covalently crosslinked to collagen through glutamine transaminase to form EGF-linker polypeptide-collagen. The protein solution taking EGF-linker polypeptide-collagen as active ingredients is low in cytotoxicity and high in biological safety, and meanwhile, the action time of the epidermal growth factor can be remarkably prolonged. In addition, a stable repairing microenvironment can be formed on the surface of the endometrium, and the endometrium injury repairing effect is remarkably improved.

The invention discloses injectable hydrogel capable of rapidly stopping bleeding and a preparation method thereof. The injectable hydrogel is prepared from a natural high-molecular compound, a natural high-molecular polymer, an organic high-molecular polymer, a catechol-like organic compound, a cross-linking agent and ultrapure water. A natural high-molecular linear polymer is combined with an organic high-molecular polymer in a non-covalent bond manner to form a macromolecular polymer, and the macromolecular polymer is used as a main network skeleton of the hydrogel to provide strength support; the catechol-like organic compound and the natural high-molecular compound form a strong non-covalent effect in a polymer chain to enhance the strength, the hemostatic property, the antibacterial property, the adhesion and the self-healing property of the organogel; besides, under the action of the cross-linking agent, the catechol-like organic compound forms a free radical group to be subjected to free radical coupling with the macromolecular polymer, so that the effect of enhancing a hydrogel network is achieved, and meanwhile, hydrogen bonds, dipole-dipole interaction, static interaction and the like can be formed with polar functional groups on the surface. The hemostatic gel is rapid in hemostasis, simple to prepare, good in biocompatibility, good in antibacterial property, injectable and degradable.

This invention provides a tetrahedral antibody comprising a first, second, third, and fourth domain, wherein the first and second domains are Fab or Fc domains; wherein each of the first and second domains comprise a first polypeptide chain comprising a first N-terminus of the domain, and a second polypeptide chain comprising a second N-terminus of the domain; wherein the first N-terminus of the first domain and the first N-terminus of the second domain are joined to each other by a non-peptidyl linkage, which can be a covalent linkage or a non-covalent linkage between first and second dimerizing polypeptides attached to the first N-termini of the first and second domains, respectively; and wherein the third and fourth domains are attached at their respective C-termini to the second N-termini of the first and second domains, respectively, or the N-termini of the first and second dimerizing polypeptides.

The invention discloses a preparation method and application of a recombinant XVII type collagen and adenosine eutectic substance. According to the invention, adenosine and recombinant XVII type collagen are combined through a non-covalent bond to form a novel supramolecular eutectic substance. The solubility and skin permeability of the eutectic substance are improved through the synergistic effect of the two substances, and the performance of fixing hair and promoting hair papilla cell proliferation is also enhanced.

A nanoparticle complex comprises a bifunctional binder capable of non-covalently binding to the lipid nanoparticle in the nanoparticle complex.

The invention relates to the technical field of preparation of organic solar cells, in particular to an organic solar cell based on a halogenated additive, and the structure level of a forward device of the solar cell sequentially comprises a transparent conductive substrate, a hole transport layer, an organic active layer, an electron transport layer and a metal electrode from bottom to top, the organic active layer comprises a polymer donor PM6, a non-fullerene electron acceptor L8-BO and a halogenated additive DFBB. Through addition of a halogenated additive DFBB, strong non-covalent bonding is formed by unique sigma-hole interaction of the halogenated additive DFBB and a receptor L8-BO, and meanwhile, the molecular stacking orientation of the active layer can be accurately regulated and controlled by the polymer electrostatic potential extreme value of the halogenated additive DFBB. The halogenated additive DFBB preferentially generates strong sigma-hole interaction with acceptor molecules, ordered accumulation of L8-BO is remarkably enhanced, meanwhile, the crystallization behavior of the donor PM6 is balanced through the synergistic halogen effect, a bicontinuous interpenetrating network structure is formed, and the photo-generated exciton yield is improved.

The invention provides bioactive conductive hydrogel as well as preparation and application thereof. The hydrogel comprises a dynamic non-covalent cross-linked network which is composed of natural macromolecules and at least comprises a reversible and environment-responsive cross-linking mode; the responsive conductive component is connected with the dynamic non-covalent cross-linked network through a covalent bond or a coordinate bond, the electrical property of the responsive conductive component changes along with the change of the wound surface microenvironment, and electrical signal feedback of the wound surface state is provided through the change of the electrical property; and the active substance is connected to the dynamic non-covalent cross-linked network through a responsive chemical bond, and the responsive chemical bond is broken under specific conditions of a wound surface microenvironment to release the active substance. Compared with the prior art, the integrated design of active oxygen monitoring and drug release is realized for the first time, the wound healing time (about 30-40%) can be remarkably shortened, the complication risk is reduced, and an innovative solution is provided for wound management in an intelligent medical mode.

The invention discloses an oligonucleotide intracellular nano delivery system based on polypeptide modification and application thereof. The system is composed of a periostin targeting sequence (SDSSD), a matrix metalloproteinase 2 (MMP2) response sequence (GPAGLLG), a cell penetrating sequence (RRRRRRRR, R9), a reactive oxygen species (ROS) scavenging and adhesion enhancing group (Gly-DOPA)) and a terminal dibenzocyclooctyne (DBCO) modified engineered polypeptide SDSSD-PEG5-YGFGG-GPAGLLG-R9-(G-DOPA) 3-K4-C-DBCO, and a target oligonucleotide miRNA-26a-A5-Azido modified by 5-polyadenylic acid (AAAAA) and an azide group (Azido), and the target oligonucleotide miRNA-26a-A5-Azido, the target oligonucleotide and assembling through a click chemical reaction and a non-covalent interaction. The nano system has good bone targeting, enzyme responsiveness, intracellular delivery effect and biological safety, can realize stable and efficient delivery of therapeutic oligonucleotides in vivo, and significantly improves the utilization efficiency and therapeutic potential of oligonucleotides. The oligonucleotide intracellular nano delivery system has a wide application prospect in the fields of clinical transformation and precise treatment of oligonucleotide drugs.

The invention discloses a salicylic acid-cyclodextrin-amino acid ternary inclusion compound and a preparation method thereof. The salicylic acid-cyclodextrin-amino acid ternary inclusion compound is formed by salicylic acid, amino acid and a cyclodextrin derivative through non-covalent bond interaction, the cyclodextrin derivative is a cross-linked beta-cyclodextrin polymer, salicylic acid molecules are included in a cavity of the cross-linked beta-cyclodextrin polymer, and the cross-linked beta-cyclodextrin polymer is a cross-linked beta-cyclodextrin polymer. And meanwhile, guanidyl or carboxyl of an amino acid side chain interacts with hydroxyl outside the cross-linked beta-cyclodextrin polymer or an exposed part of an included salicylic acid molecule. According to the invention, a cross-linked beta-cyclodextrin polymer is used, arginine is introduced as a synergist, a salicylic acid-cross-linked beta-cyclodextrin polymer-arginine ternary clathrate compound is constructed, and through charge neutralization and hydrogen bond network synergistic effect, clathration efficiency is significantly improved, and water solubility of salicylic acid is improved.

The invention discloses a chitosan-casein peptide nano-particle and a preparation method and application thereof, and belongs to the technical field of food manufacturing, chitosan and casein peptide are combined into a nano-composite with the particle size of 10-1000 nm through electrostatic interaction in a non-covalent binding mode, and the nano-composite is used for preparing the chitosan-casein peptide nano-particle. A more stable oil-in-water emulsion can be prepared by utilizing the nano composite; the invention also provides a preparation method and application of the chitosan-casein peptide nanocomposite, and a preparation method of the oil-in-water emulsion. The nano-composite prepared by the invention has relatively strong oxidation resistance, foamability and foaming stability when the ratio of chitosan to casein peptide is 1: 1, and an oil-in-water emulsion prepared from the nano-composite has good storage stability, pH stability and ion stability. The preparation method of the nanocomposite is simple and low in cost, and has a good application prospect.

The invention is applicable to the technical field of polymer biomedical hydrogel materials, and provides a preparation method and application of multifunctional agarose-based particle composite hydrogel based on liquid-liquid phase separation, and the agarose-based particle composite hydrogel is a product formed by introducing microsphere particles into an agarose hydrogel body matrix; the microsphere particles are formed by a prepolymer and sodium lignin sulfonate through phase separation mediated by a composite behavior based on non-covalent interaction; the prepolymer is obtained by carrying out amine-epoxy reaction on an amino compound and an epoxy compound in water. According to the prepared agarose-based particle composite hydrogel, a microsphere particle structure is formed on the surface of an agarose matrix while positively charged amino groups and sodium lignin sulfonate are introduced, so that the multifunctional agarose-based particle composite hydrogel is prepared.

The self-assembled nano material comprises a Janus-based nano tube, wherein the Janus-based nano tube comprises at least one compound represented by a formula I to a formula XII, or a pharmaceutically acceptable salt of the compound. Also described are compositions comprising the Janus-based nanotubes, comprising a biologically active molecule covalently or non-covalently attached to the self-assembled nanomaterial.

The invention discloses injectable hydrogel as well as a preparation method and application thereof. The hydrogel is a chemical-physical double-network cross-linked hydrogel prepared from a blended solution with magnesium acrylate, carboxymethyl chitosan and phytic acid as main components. Wherein covalent cross-linking is derived from a magnesium polyacrylate network constructed by free radical polymerization reaction. Non-covalent cross-linking is derived from hydrogen bonds and electrostatic interaction among components in an interpenetrating network and a carboxymethyl chitosan chain entanglement network formed by gradual induction in the application process of a physiological environment. In the preparation process, the pH value of a reaction system is controlled by controlling the concentration of phytic acid, magnesium ions are chelated, then the structural strength of the hydrogel is controlled, and the injectable effect is achieved. Meanwhile, phytic acid can be chelated with protein, so that the adhesion of the phytic acid to tissues is enhanced. The preparation process is simple and convenient, easy to control and suitable for large-scale industrial production, and all the raw materials are easy to obtain and low in price. The hydrogel has high adhesion efficiency and wet adhesion strength to tissue.

The invention relates to a cationic tannin and prolamin composite nano system and a preparation method and application thereof.The cationic tannin and prolamin composite nano system is prepared through the steps that cationic tannin and prolamin are dissolved in an alcoholic solution through an anti-solvent dispersion method, then the alcoholic solution is dropwise added and dispersed in water, and the cationic tannin and prolamin composite nano system is obtained. Nano-particles are formed through self-assembly under the interaction of non-covalent acting force between cationic tannin and prolamin in an aqueous solution, and the composite nano-system is applied to water treatment. Compared with the prior art, the water treatment agent is good in storage stability and has excellent performance of removing antibiotic pollution in a water body.

The invention discloses an asymmetric gemini-like surfactant constructed based on non-covalent bonds as well as a preparation method and application of the asymmetric gemini-like surfactant, and belongs to the technical field of fire-fighting foam extinguishing agents. The preparation method comprises the following steps: mixing medium-chain fatty acid and polyether amine D230 according to a certain molar ratio in a nitrogen atmosphere, heating in a water bath to a reaction temperature, fully stirring for 15 minutes, and constructing through a non-covalent bond to obtain an intermediate; and adding long-chain fatty acid into the intermediate according to a certain molar ratio, keeping the reaction temperature, continuously stirring for 15 minutes, obtaining a product through non-covalent bond construction, and carrying out vacuum drying for more than 12 hours to obtain the asymmetric gemini-like surfactant. The prepared asymmetric gemini-like surfactant has the advantages of being high in foaming capacity, long in half-life period and low in surface tension, and is suitable for replacing a fluorocarbon surfactant to be used as a foaming agent in an environment-friendly foam extinguishing agent.

This invention belongs to the field of cosmetic technology, specifically a glycyrrhizin-based composite nanoparticle containing sclerotherapy, BPOXY, and collagen, along with its preparation method and applications. The invention first combines glycyrrhizin and glycyrrhizic acid via non-covalent bonds to obtain a glycyrrhizin-glycyrrhizic acid eutectic structure that overcomes the solubility problem of glycyrrhizin. Then, a BPOXY-collagen mixture is used to coat the glycyrrhizin-glycyrrhizic acid eutectic structure, yielding glycyrrhizin-based composite nanoparticles containing sclerotherapy, BPOXY, and collagen. The glycyrrhizin-based composite nanoparticles containing sclerotherapy, BPOXY, and collagen obtained using this method exhibit good water solubility of glycyrrhizin, a simple composition, high stability, and minimal risk of allergic reactions. Furthermore, it enhances the skin permeability of glycyrrhizin, collagen, and BPOXY, resulting in a synergistic effect and improved bioavailability.

This invention discloses an AfBPP-based active molecular probe for thiostreptin, its preparation, and its application, belonging to the field of chemical biology. This invention introduces a bifunctional tag integrating a photocrosslinking group (bisacrididine) and a bioorthogonal reactive group (alkynyl group) into the structure of thiostreptin. While retaining the original biological activity of the parent compound, it endows the probe with highly efficient probe function, solving the technical problem of target loss during washing and purification of traditional non-covalent probes. After target labeling, the probe can specifically connect to reporter groups such as fluorescein or biotin through click-chemical reactions, achieving efficient enrichment of drug targets. Combined with mass spectrometry analysis, it enables global identification of potential targets in cells or complex biological samples at the omics level, such as chemical proteomics, providing a powerful molecular tool for in-depth revelation of the potential targets and pharmacological mechanisms of thiostreptin.

The present disclosure provides novel and improved IL-15 fusion proteins for treating cancer and other disorders. In various embodiments, the fusion protein of the present invention has two functional domains: an IL-15 / IL-15RαSushi domain (also referred to herein as "IL-15 / IL-15RαSushi complex") and an Fc domain, each of which can take different forms and is configured so that IL-15 is fused to the C-terminus of the Fc domain and co-expressed and non-covalently complexed with IL-15RαSushi. Importantly, the fusion protein of the present invention solves several defects observed in the IL-15 therapeutic agents evaluated to date; specifically, the fusion protein shows an extended half-life of IL-15 in vivo and exhibits better preclinical activity than rIL-15 or related cytokine therapeutics.

The invention belongs to the technical field of medicines, and discloses a chrysin and piperazine eutectic, a preparation method, a composition and application thereof. Specifically, the invention discloses an eutectic substance formed by combining chrysin and piperazine through a non-covalent bond, and the molecular formula of the eutectic substance is (C15H10O4). (C4H10N2) 0.5, the invention relates to a preparation method of a chrysin and piperazine eutectic. The chrysin and piperazine eutectic is applied to preparation of drugs with the effects of preventing and treating cardiovascular diseases, resisting oxidation, resisting cancer, resisting virus, resisting hypertension, reducing blood fat, reducing blood sugar, resisting bacteria, diminishing inflammation and the like.

A non-covalent complex of an albumin molecule and a hydrophobic ligand, compositions containing the same, and methods of use thereof are provided. The present complex may find use in delivering the hydrophobic ligand to microorganisms that have albumin-binding outer surfaces, such as a cell wall.

The invention belongs to the field of natural plant extraction, and particularly relates to a method for extracting volatile oil from pepper. The method comprises the following steps: pulverizing a pepper raw material to obtain pepper powder, protecting an active component and modified maltodextrin, mixing, soaking the pepper powder in an obtained efficient leaching suspension, ultrasonically crushing the soaked mixture, and carrying out primary extraction to obtain primary extracted oil with obviously improved purity; the preparation method comprises the following steps: mixing a composite solvent formed through non-covalent interaction and combination with primarily extracted oil, filtering, carrying out molecular distillation on the obtained permeate, reducing the boiling point of an active ingredient by the composite solvent through a solvation effect, reducing thermal degradation, and remarkably improving the purity of the active ingredient while retaining the flavor through non-covalent pre-assembly-molecular distillation synergy. Light-phase fractions are collected after molecular distillation, and the prepared pepper volatile oil is high in active ingredient content, good in flavor retention, few in impurities and pure in color.

Provided are modified virus-like particles (VLPs) of paramyxoviruses, compositions containing them, methods of using the VLPs for delivery of any particular protein of interest to any of a variety of cells, kits that contain expression vectors for making, using and detecting VLPs, and methods for screening for anti-viral compounds using the VLPs. The modified VLPs contain a contiguous recombinant polypeptide that contains i) all or a segment of a C-terminal domain of a paramyxovirus nucleocapsid protein and ii) a polypeptide sequence of a distinct protein. Non-covalent complexes of paramyxovirus M protein and fusion proteins that contain a C-terminal domain of a paramyxovirus nucleocapsid protein and a polypeptide sequence of a distinct protein are provided, as are non-covalent complexes of cells, and cell receptors, with modified VLPs.

The application relates to a fusion protein and application thereof in the field of biotechnology. A polypeptide fragment for specifically recognizing a single-molecule phospholipid membrane and a polypeptide fragment for specifically recognizing a tissue or a cell are connected to form a fusion protein which can be specifically combined to a fat body surface in a non-covalent manner, so that precise targeting of the fat body is realized. The fat body targeting peptide segment can be widely used in the fields of precise drug delivery and vaccine preparation, so as to be used for treating diseases such as cancer, infectious diseases and metabolic diseases. Lung tissues and breast cancer cells are taken as target points, and good targeting of the fat body is realized.

Embodiments herein relate to chemical sensors based on the non-covalent surface modification of graphene with compounds containing hydrazine or hydroxylamine functional groups for the detection of aldehyde and ketone-bearing analytes. In an embodiment, a medical device is included having a graphene varactor included a graphene layer and a self-assembled monolayer disposed on an outer surface of the graphene layer through electrostatic interactions between a partial positive charge on hydrogen atoms of one or more hydrocarbons of the self-assembled monolayer and a π-electron system of graphene. The self-assembled monolayer can include one or more compounds having one or more hydrazine groups or hydroxylamine groups, substituted hydrazine or hydroxylamine groups, or derivatives thereof. Other embodiments are also included herein.

Provided is a method for improving the stability of urate oxidase. The inventors have discovered that combining an active ingredient urate oxidase or chemically modified urate oxidase with a stabilizer xanthine through a non-covalent bond can significantly improve the in vivo and in vitro stability of urate oxidase and chemically modified urate oxidase in the form of a tetramer, thereby effectively improving the stability of urate oxidase.

Provided herein a supramolecular assembly comprising a solid porous particle comprising a single-stranded polynucleotide encapsulated by non-covalent organic structure. Specifically, the non-covalent organic structure is melamine-cyanurate, and the single-stranded polynucleotide is ssDNA or ssRNA.

The invention relates to the technical field of biological medicine, and particularly discloses an NSD protein targeted inhibitor and a preparation method thereof.The NSD protein targeted inhibitor is formed by assembling RK-0080552, rosmarinic acid, ferulic acid and TAT cell-penetrating peptide through non-covalent bonds, amino of the RK-0080552, phenolic hydroxyl of the rosmarinic acid and phenolic hydroxyl of the ferulic acid form a hydrogen bond, and the TAT cell-penetrating peptide forms a non-covalent bond. Arginine residues of the TAT cell-penetrating peptide are combined with carboxyl groups of rosmarinic acid and ferulic acid through electrostatic interaction to form a stable three-dimensional supramolecular structure; the preparation method comprises the following steps: respectively dissolving the components, mixing and crystallizing in proportion, washing, homogenizing at high pressure, and freeze-drying to obtain the NSD protein targeted inhibitor. According to the invention, drug activity enhancement and targeted delivery are realized through a supramolecular co-crystal technology, and the drug can be used for treating NSD2 high-expression tumors such as multiple myeloma and acute myelogenous leukemia, and has significant clinical application value.

This document relates to non-covalently bound complexes including Docetaxel and human serum albumin, and to compositions comprising such complexes. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the composition is a clear aqueous solution when the composition is dissolved in an aqueous solution, and wherein the composition has a solubility in an aqueous solution of at least 10 mg / ml. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a weight ratio from about 1:50 to about 1:1000. This document also relates to compositions consisting essentially of Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a weight ratio from about 1:50 to about 1:1000. The pH of the docetaxel compositions of the present disclosure is from about 5 to about 8.

The invention belongs to the technical field of semiconductor materials and devices, and discloses a photoelectric functional material for an organic transistor and a preparation method and application of the photoelectric functional material. A C-H activation strategy is adopted, two kinds of novel organic conjugated small molecules p-Ph2FTT and o-Ph2FTT containing F.H non-covalent bond conformation locks are synthesized, and the novel organic conjugated small molecules p-Ph2FTT and o-Ph2FTT containing F.H non-covalent bond conformation locks are synthesized. The molecule has excellent planarity, wide forbidden band (2.8 eV) and low HOMO energy level.